Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population.

Baloxavir, a cap-dependent endonuclease inhibitor, was recently approved for treatment of severe influenza infections. Combining baloxavir with oseltamivir has been proposed to increase the response rate. We report 2 hematopoietic cell transplant recipients with severe influenza infections who were treated with this combination and discuss possible reasons for their different responses.
Competing Interests: Declaration of competing interest Roy F. Chemaly received research grants from Gilead, Janssen, and Ansun pharmaceuticals. He received personnel fees from Ansun pharmaceuticals, Ablynx, ADMA Biologics, Janssen, and Kyorin.
(Copyright © 2021 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.)